BR9809173A - Alternatively targeted adenoviruses - Google Patents

Alternatively targeted adenoviruses

Info

Publication number
BR9809173A
BR9809173A BR9809173-5A BR9809173A BR9809173A BR 9809173 A BR9809173 A BR 9809173A BR 9809173 A BR9809173 A BR 9809173A BR 9809173 A BR9809173 A BR 9809173A
Authority
BR
Brazil
Prior art keywords
adenovirus
substrate
present
provides
trimer
Prior art date
Application number
BR9809173-5A
Other languages
Portuguese (pt)
Inventor
Thomas J Wickham
Imre Kovesdi
Petrus W Roelvink
David Einfeld
Douglas E Brough
Alena Lizonova
Grant Yonehiro
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of BR9809173A publication Critical patent/BR9809173A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<B>ADENOVìRUS ALTERNATIVAMENTE DIRECIONADOS<D> A presente invenção provê um trímero compreendendo três monómeros, cada um tendo um terminal amino de uma proteína de fibra adenoviral e um domínio de trimerização. O trímero apresenta uma afinidade reduzida para um substrato nativo, em comparação com um trímero de fibra adenoviral nativo. A presente invenção provê, ainda, um adenovírus incorporando o trímero da presente invenção. A presente invenção também provê uma linhagem de célula expressando um receptor de superfície de célula não-nativo, ao qual liga-se um adenovírus tendo um ligante para o receptor, e um método de propagar um adenovírus utilizando a linhagem de célula. A presente invenção também provê um método de purificar um adenovírus tendo um ligante para um substrato de uma composição compreendendo o adenovírus. O método envolve a exposição da composição ao substrato, sob condições que promovem o ligante a ligar-se, seletivamente, ao substrato. A presente invenção provê, ainda, um método de inativar um adenovírus tendo um ligante que reconhece um substrato carregado por linfa ou sangue, expondo o vírus ao substrato. No sangue ou linfa, o ligante liga seu substrato, adsorvendo, deste modo, o vírus livre do sangue ou linfa. Adicionalmente, a presente invenção provê uma proteína de bloqueio quimérica, compreendendo um substrato para uma fibra de adenovírus, e um método para interferir com a ligação de receptor adenoviral, incubando um adenovírus com tal proteína de bloqueio quimérica, em uma solução tal que a proteína de bloqueio quimérica liga a fibra.<B> ALTERNATIVELY TARGETED ADENOVIRUS <D> The present invention provides a trimer comprising three monomers, each having an amino terminus of an adenoviral fiber protein and a trimerization domain. The trimer has a reduced affinity for a native substrate, compared to a native adenoviral fiber trimer. The present invention further provides an adenovirus incorporating the trimer of the present invention. The present invention also provides a cell line expressing a non-native cell surface receptor, to which an adenovirus having a ligand for the receptor is attached, and a method of propagating an adenovirus using the cell line. The present invention also provides a method of purifying an adenovirus having a linker for a substrate of a composition comprising the adenovirus. The method involves exposing the composition to the substrate, under conditions that promote the binder to selectively bind to the substrate. The present invention further provides a method of inactivating an adenovirus having a ligand that recognizes a substrate loaded with lymph or blood, exposing the virus to the substrate. In the blood or lymph, the ligand binds its substrate, thus adsorbing the virus free from the blood or lymph. In addition, the present invention provides a chimeric blocking protein, comprising a substrate for an adenovirus fiber, and a method for interfering with adenoviral receptor binding, by incubating an adenovirus with such a chimeric blocking protein, in a solution such that the protein chimeric blocking bond connects the fiber.

BR9809173-5A 1997-05-28 1998-05-28 Alternatively targeted adenoviruses BR9809173A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4784997P 1997-05-28 1997-05-28
US7166898P 1998-01-16 1998-01-16
PCT/US1998/011024 WO1998054346A1 (en) 1997-05-28 1998-05-28 Alternatively targeted adenovirus

Publications (1)

Publication Number Publication Date
BR9809173A true BR9809173A (en) 2000-08-01

Family

ID=26725500

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809173-5A BR9809173A (en) 1997-05-28 1998-05-28 Alternatively targeted adenoviruses

Country Status (10)

Country Link
EP (1) EP0988390A1 (en)
JP (1) JP2001518806A (en)
BR (1) BR9809173A (en)
CA (1) CA2291323A1 (en)
HU (1) HUP0002070A2 (en)
IL (1) IL133010A0 (en)
NZ (1) NZ501140A (en)
PL (1) PL337130A1 (en)
SK (1) SK159999A3 (en)
WO (1) WO1998054346A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767975B2 (en) * 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
WO2000046364A1 (en) * 1999-02-05 2000-08-10 The Uab Research Foundation Fiber receptor-independent system for the propagation of adenoviral vectors
JP2000279178A (en) * 1999-02-24 2000-10-10 Japan Found Cancer Res Virus vector
EP1593742A3 (en) * 1999-06-01 2006-02-01 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
DE60018920T2 (en) * 1999-06-01 2006-04-13 University Of Washington, Seattle RECOMBINANT ADENOVIRAL VECTORS EXPRESSING CHIMERIC FIBER PROTEINS FOR CELL SPECIFIC INFECTION AND GENOMIC INTEGRATION
JP5043271B2 (en) 2000-04-12 2012-10-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ Peptide-based compounds
CA2407518A1 (en) * 2000-04-26 2001-11-01 Crucell Holland B.V. Adenovirus vectors with knobless fibers, and their uses
EP1167533A1 (en) * 2000-06-23 2002-01-02 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Methods and means for the complementation of viral protein expression in stable cell lines
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
NO20004795D0 (en) 2000-09-26 2000-09-26 Nycomed Imaging As Peptide-based compounds
HU230901B1 (en) 2001-07-10 2019-01-28 Ge Healthcare Limited Peptide-based compounds and pharmaceutical compositions containing them
FR2842823A1 (en) * 2002-07-25 2004-01-30 Inst Nat Sante Rech Med MODIFIED ADENOVIRUSES FOR TARGETING B-LYMPHOCYTES
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
EP1613757A2 (en) 2003-03-28 2006-01-11 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
DE602004025726D1 (en) 2003-11-14 2010-04-08 Genvec Inc PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF LOCALLY ADVANCED PRIMARY INOPERABLES PANCREATIC CARCINOMA (LAPC).
EP2567967A3 (en) 2004-04-12 2013-08-21 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of using adenoviral vectors to induce an immune response
CA2620495A1 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
BRPI0618441B8 (en) 2005-11-10 2021-07-27 Genvec Inc adenoviral vector
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
WO2010075058A1 (en) 2008-12-23 2010-07-01 Ge Healthcare Limited Application of 99mtc peptide-based compound as a bone marrow imaging agent
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
EA201270607A1 (en) 2009-11-09 2012-09-28 Генвек, Инк. MONKEY MONKEY ADENOVIRUS AND METHODS FOR USING IT
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (en) 2010-12-20 2019-02-20 GenVec, Inc. Adenoviral vector-based dengue fever vaccine
EP2855669B1 (en) 2012-05-29 2018-10-10 GenVec, Inc. Modified serotype 28 adenoviral vectors
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
TWI710635B (en) 2014-10-09 2020-11-21 美商珍維克公司 Adenoviral vector encoding human atonal homolog-1 (hath1)
EP3072900A1 (en) 2015-03-27 2016-09-28 Medizinische Hochschule Hannover Anti-tumour medicament based on adenovirus
JP7054527B2 (en) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ High-throughput assay to measure adenovirus replication kinetics
JP7015551B2 (en) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ Exogenous gene expression in therapeutic adenovirus to minimize its impact on viral dynamics
CA3038968A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same

Also Published As

Publication number Publication date
JP2001518806A (en) 2001-10-16
WO1998054346A1 (en) 1998-12-03
EP0988390A1 (en) 2000-03-29
CA2291323A1 (en) 1998-12-03
NZ501140A (en) 2001-07-27
IL133010A0 (en) 2001-03-19
SK159999A3 (en) 2000-06-12
HUP0002070A2 (en) 2000-10-28
PL337130A1 (en) 2000-07-31

Similar Documents

Publication Publication Date Title
BR9809173A (en) Alternatively targeted adenoviruses
Tarsio et al. Decreased interaction of fibronectin, type iv collagen, and heparin due to nonenzymic glycation. Implications for diabetes mellitus
Ohta et al. The mechanism of carbohydrate-mediated complement activation by the serum mannan-binding protein.
PT1140175E (en) ANTIBODIES FOR VEGF-D TRUNCATED AND ITS UTILIZATIONS
DE69232309D1 (en) MOSTLY PURE RECEPTOR-LIKE, TGF-BETA-1 BINDING MOLECULES AND THEIR USE
DK0930366T3 (en) Binding domains in Delta proteins
BR0011849A (en) Enhanced lm609 Grafted Antibodies
BR9815289A (en) Modified immunoglobulin, molecule, isolated nucleic acid, cell containing the same, recombinant non-human animal, pharmaceutical composition, vaccine composition, processes for identifying or measuring or detecting a cancer antigen, an antigen from an infectious disease agent, a ligand, and a receptor in a sample. to be tested, kits for detecting a cancer antigen, an infectious disease agent antigen, a cell receptor for an infectious disease agent, a ligand, and a cancer antigen, diagnostic processes or testing for the presence of or a predisposition for the development of a cancer by the increased presence of a cancer antigen, and for the presence of an infectious disease, treatment or prevention of a cancer by the presence of a cancer antigen, of an infectious disease typified by the presence of an antigen infectious disease agent, and a disease caused by an infectious disease agent that binds to a cell receptor, processes for modulating activity of a first member of a binding pair, process for producing a modified immunoglobulin, process for producing a modified immunoglobulin nucleic acid, and, isolated nucleic acid
BRPI0606790A2 (en) isolated human antibody or antigen binding portion thereof, isolated polypeptide, composition, isolated nucleic acid, host cell expression vector, rabies vaccine, kit, use of an isolated human monoclonal antibody or antigen binding portion thereof, or an effective amount of a composition, a method for identifying an antibody or fragment thereof, antibody or fragment thereof, antibody or fragment thereof, and glycoprotein.
BRPI0518994A2 (en) br3-binding antibodies or polypeptides, their uses and liquid formulations
BRPI0507019A (en) composition, antibody use, antibody, msrv / herv-w env-su use
Rexin et al. Structure of the glucocorticoid receptor in intact cells in the absence of hormone.
CA2296737A1 (en) Ligand for herpes simplex virus entry mediator and methods of use
ATE122057T1 (en) MONOCLONAL ANTIBODIES AGAINST PROTEIN C.
IL134011A0 (en) Adipocyte-specific protein homologs
WO1994021800A3 (en) Protein tyrosine phosphatase ptp-s31
GB2368641A (en) Methods and compositions fo assaying analytes
DK0937153T3 (en) Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
ATE542138T1 (en) HER-2 BINDING ANTAGONISTS
CA2524002A1 (en) Sars-related proteins
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
DE59508137D1 (en) SPECIFIC BINDING SUBSTANCES FOR ANTIBODIES AND THEIR USE FOR IMMUNOASSAYS OR VACCINE
ES2082132T3 (en) COMPOSITION CONTAINING AT LEAST TWO DIFFERENT ANTIBODIES OR FRAGMENTS OF THEM.
Wu et al. Multi‐antennary Galβ1→ 4GlcNAc and Galβ1→ 3GalNAc clusters as important ligands for a lectin isolated from the sponge Geodia cydonium
BR112023020193A2 (en) Biespecific bespecific protein, pharmaceutical composition, nucleic acid, vector, host cell, bespecific antibody, cancer treatment or prevention methods and to intensify an immune response, and uses of a bespecific bespecific and nucleic acid protein.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.